Loading…
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to hi...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS 2021-02, Vol.118 (5), p.1-8 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3 |
---|---|
cites | cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3 |
container_end_page | 8 |
container_issue | 5 |
container_start_page | 1 |
container_title | Proceedings of the National Academy of Sciences - PNAS |
container_volume | 118 |
creator | Sasisekharan, Varun Pentakota, Niharika Jayaraman, Akila Tharakaraman, Kannan Wogan, Gerald N. Narayanasami, Uma |
description | Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome. |
doi_str_mv | 10.1073/pnas.2021615118 |
format | article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7865175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>27006148</jstor_id><sourcerecordid>27006148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</originalsourceid><addsrcrecordid>eNpdkc1r3DAQxU1pabZpzz21CHLpxYkky7Z0KYSlSQOBQNP2KmR5vOvFllyNHNhr__LI3XT7cRrQ-81j9F6WvWX0nNG6uJicwXNOOatYyZh8lq0YVSyvhKLPsxWlvM6l4OIke4W4o5SqUtKX2UlRCFGVjK-yn3chbv3GOzOQfhxn5w2i2SPpfCA3m2tiXOwb3_aAJHpyf_nlPl_77zn_JWzAIQnwAGk7bk08WEB6wsk7BDIYjEga2HvXEkFGTyaPCRsGB4hkYeLr7EVnBoQ3T_M0-3b16ev6c357d32zvrzNrRBFzEtbSWWhNSXwrmBlBQ2rue2UUsLKVhXU2saIurS8pk0n2pYa06iOKtpwYFCcZh8PvtPcjNBacDGYQU-hH03Ya296_a_i-q3e-Addy5RVXSaDD08Gwf-YAaMee7QwDMaBn1FzUctSKioX9Ow_dOfnkEJeKJmKYLJmibo4UDZ4xADd8RhG9dKvXvrVf_pNG-___sOR_11oAt4dgB1GH456ioRWTMjiEQIZrbk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2480001871</pqid></control><display><type>article</type><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>PubMed Central</source><creator>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</creator><creatorcontrib>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</creatorcontrib><description>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</description><identifier>ISSN: 0027-8424</identifier><identifier>ISSN: 1091-6490</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.2021615118</identifier><identifier>PMID: 33446512</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Adaptive immunity ; Adult ; Antibodies ; Antibodies, Viral - blood ; Antibody response ; Antigens ; Biological Sciences ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - immunology ; Female ; Humans ; IgG antibody ; Illnesses ; Immune response ; Immune system ; Immunity ; Immunity, Humoral ; Immunoassay ; Immunoassays ; Immunoglobulin G ; Immunoglobulin G - blood ; Infections ; Longitudinal Studies ; Male ; Middle Aged ; Morbidity ; Neutralizing ; Nucleocapsids ; Pandemics ; Respiratory diseases ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome coronavirus 2 ; Spike protein ; Vaccination ; Viral diseases</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2021-02, Vol.118 (5), p.1-8</ispartof><rights>Copyright © 2021 the Author(s). Published by PNAS.</rights><rights>Copyright National Academy of Sciences Feb 2, 2021</rights><rights>Copyright © 2021 the Author(s). Published by PNAS. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</citedby><cites>FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</cites><orcidid>0000-0002-0620-3189 ; 0000-0002-9663-0220</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/27006148$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/27006148$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33446512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sasisekharan, Varun</creatorcontrib><creatorcontrib>Pentakota, Niharika</creatorcontrib><creatorcontrib>Jayaraman, Akila</creatorcontrib><creatorcontrib>Tharakaraman, Kannan</creatorcontrib><creatorcontrib>Wogan, Gerald N.</creatorcontrib><creatorcontrib>Narayanasami, Uma</creatorcontrib><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</description><subject>Adaptive immunity</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Biological Sciences</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - immunology</subject><subject>Female</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Illnesses</subject><subject>Immune response</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunity, Humoral</subject><subject>Immunoassay</subject><subject>Immunoassays</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - blood</subject><subject>Infections</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Neutralizing</subject><subject>Nucleocapsids</subject><subject>Pandemics</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - immunology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike protein</subject><subject>Vaccination</subject><subject>Viral diseases</subject><issn>0027-8424</issn><issn>1091-6490</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkc1r3DAQxU1pabZpzz21CHLpxYkky7Z0KYSlSQOBQNP2KmR5vOvFllyNHNhr__LI3XT7cRrQ-81j9F6WvWX0nNG6uJicwXNOOatYyZh8lq0YVSyvhKLPsxWlvM6l4OIke4W4o5SqUtKX2UlRCFGVjK-yn3chbv3GOzOQfhxn5w2i2SPpfCA3m2tiXOwb3_aAJHpyf_nlPl_77zn_JWzAIQnwAGk7bk08WEB6wsk7BDIYjEga2HvXEkFGTyaPCRsGB4hkYeLr7EVnBoQ3T_M0-3b16ev6c357d32zvrzNrRBFzEtbSWWhNSXwrmBlBQ2rue2UUsLKVhXU2saIurS8pk0n2pYa06iOKtpwYFCcZh8PvtPcjNBacDGYQU-hH03Ya296_a_i-q3e-Addy5RVXSaDD08Gwf-YAaMee7QwDMaBn1FzUctSKioX9Ow_dOfnkEJeKJmKYLJmibo4UDZ4xADd8RhG9dKvXvrVf_pNG-___sOR_11oAt4dgB1GH456ioRWTMjiEQIZrbk</recordid><startdate>20210202</startdate><enddate>20210202</enddate><creator>Sasisekharan, Varun</creator><creator>Pentakota, Niharika</creator><creator>Jayaraman, Akila</creator><creator>Tharakaraman, Kannan</creator><creator>Wogan, Gerald N.</creator><creator>Narayanasami, Uma</creator><general>National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0620-3189</orcidid><orcidid>https://orcid.org/0000-0002-9663-0220</orcidid></search><sort><creationdate>20210202</creationdate><title>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</title><author>Sasisekharan, Varun ; Pentakota, Niharika ; Jayaraman, Akila ; Tharakaraman, Kannan ; Wogan, Gerald N. ; Narayanasami, Uma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunity</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Biological Sciences</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - immunology</topic><topic>Female</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Illnesses</topic><topic>Immune response</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunity, Humoral</topic><topic>Immunoassay</topic><topic>Immunoassays</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - blood</topic><topic>Infections</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Neutralizing</topic><topic>Nucleocapsids</topic><topic>Pandemics</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - immunology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike protein</topic><topic>Vaccination</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasisekharan, Varun</creatorcontrib><creatorcontrib>Pentakota, Niharika</creatorcontrib><creatorcontrib>Jayaraman, Akila</creatorcontrib><creatorcontrib>Tharakaraman, Kannan</creatorcontrib><creatorcontrib>Wogan, Gerald N.</creatorcontrib><creatorcontrib>Narayanasami, Uma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasisekharan, Varun</au><au>Pentakota, Niharika</au><au>Jayaraman, Akila</au><au>Tharakaraman, Kannan</au><au>Wogan, Gerald N.</au><au>Narayanasami, Uma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2021-02-02</date><risdate>2021</risdate><volume>118</volume><issue>5</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>0027-8424</issn><issn>1091-6490</issn><eissn>1091-6490</eissn><abstract>Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>33446512</pmid><doi>10.1073/pnas.2021615118</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0620-3189</orcidid><orcidid>https://orcid.org/0000-0002-9663-0220</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8424 |
ispartof | Proceedings of the National Academy of Sciences - PNAS, 2021-02, Vol.118 (5), p.1-8 |
issn | 0027-8424 1091-6490 1091-6490 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7865175 |
source | JSTOR Archival Journals and Primary Sources Collection; PubMed Central |
subjects | Adaptive immunity Adult Antibodies Antibodies, Viral - blood Antibody response Antigens Biological Sciences Coronaviridae Coronaviruses COVID-19 COVID-19 - immunology Female Humans IgG antibody Illnesses Immune response Immune system Immunity Immunity, Humoral Immunoassay Immunoassays Immunoglobulin G Immunoglobulin G - blood Infections Longitudinal Studies Male Middle Aged Morbidity Neutralizing Nucleocapsids Pandemics Respiratory diseases SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccination Viral diseases |
title | Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A11%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Orthogonal%20immunoassays%20for%20IgG%20antibodies%20to%20SARS-CoV-2%20antigens%20reveal%20that%20immune%20response%20lasts%20beyond%204%20mo%20post%20illness%20onset&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Sasisekharan,%20Varun&rft.date=2021-02-02&rft.volume=118&rft.issue=5&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.2021615118&rft_dat=%3Cjstor_pubme%3E27006148%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-5c689ceda5e2f3156eb172cf9994c8d930ccba475c270bf4dd0aab9f090b2e1e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2480001871&rft_id=info:pmid/33446512&rft_jstor_id=27006148&rfr_iscdi=true |